Read a new publication from Oncowitan: The repurposing of Epalrestat, an atypical thiazolidinone derivative targeting aldose reductase enzymes AKR1B1 and AKR1B10, is discussed. A novel approach to treat chemo-resistant cancers.

Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer, European Journal of Pharmacology (2022)

Read here

Categories: News